192 related articles for article (PubMed ID: 36173300)
1. Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability.
Stracquadanio S; Bonomo C; Marino A; Bongiorno D; Privitera GF; Bivona DA; Mirabile A; Bonacci PG; Stefani S
Microbiol Spectr; 2022 Oct; 10(5):e0234722. PubMed ID: 36173300
[TBL] [Abstract][Full Text] [Related]
2. Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.
Poirel L; Sadek M; Nordmann P
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0087721. PubMed ID: 34252309
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.
Malik S; Kaminski M; Landman D; Quale J
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868330
[TBL] [Abstract][Full Text] [Related]
4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
5. Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii.
Raro OHF; Bouvier M; Kerbol A; Decousser JW; Poirel L; Nordmann P
Eur J Clin Microbiol Infect Dis; 2023 Dec; 42(12):1511-1518. PubMed ID: 37910268
[TBL] [Abstract][Full Text] [Related]
6. Induced Heteroresistance in Carbapenem-Resistant
Mezcord V; Escalante J; Nishimura B; Traglia GM; Sharma R; Vallé Q; Tuttobene MR; Subils T; Marin I; Pasteran F; Actis LA; Tolmasky ME; Bonomo RA; Rao G; Ramirez MS
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511511
[TBL] [Abstract][Full Text] [Related]
7. Role of transcriptomic and genomic analyses in improving the comprehension of cefiderocol activity in
Stracquadanio S; Nicolosi A; Privitera GF; Massimino M; Marino A; Bongiorno D; Stefani S
mSphere; 2024 Jan; 9(1):e0061723. PubMed ID: 38078714
[TBL] [Abstract][Full Text] [Related]
8. Tigecycline Heteroresistance and Resistance Mechanism in Clinical Isolates of Acinetobacter baumannii.
Jo J; Ko KS
Microbiol Spectr; 2021 Oct; 9(2):e0101021. PubMed ID: 34523993
[TBL] [Abstract][Full Text] [Related]
9. Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.
McLeod SM; Shapiro AB; Moussa SH; Johnstone M; McLaughlin RE; de Jonge BLM; Miller AA
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133555
[TBL] [Abstract][Full Text] [Related]
10. A Selective Culture Medium for Screening Cefiderocol Resistance in
Ibrahim A; Bouvier M; Sadek M; Decousser JW; Poirel L; Nordmann P
J Clin Microbiol; 2023 Jul; 61(7):e0188322. PubMed ID: 37338403
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis of PER-1-Mediated Cefiderocol Resistance and Synergistic Inhibition of PER-1 by Cefiderocol in Combination with Avibactam or Durlobactam in Acinetobacter baumannii.
Liu X; Lei T; Yang Y; Zhang L; Liu H; Leptihn S; Yu Y; Hua X
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0082822. PubMed ID: 36377939
[TBL] [Abstract][Full Text] [Related]
12.
Abdul-Mutakabbir JC; Nguyen L; Maassen PT; Stamper KC; Kebriaei R; Kaye KS; Castanheira M; Rybak MJ
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0264620. PubMed ID: 34125590
[TBL] [Abstract][Full Text] [Related]
13. Role of β-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species.
Mezcord V; Wong O; Pasteran F; Corso A; Tolmasky ME; Bonomo RA; Ramirez MS
Int J Antimicrob Agents; 2023 Jan; 61(1):106700. PubMed ID: 36470509
[No Abstract] [Full Text] [Related]
14. Susceptibility, phenotypes of resistance, and extended-spectrum β-lactamases in Acinetobacter baumannii strains.
Sacha P; Wieczorek P; Ojdana D; Czaban S; Kłosowska W; Jurczak A; Tryniszewska E
Folia Histochem Cytobiol; 2012 Apr; 50(1):46-51. PubMed ID: 22532135
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam.
Wareth G; Linde J; Hammer P; Nguyen NH; Nguyen TNM; Splettstoesser WD; Makarewicz O; Neubauer H; Sprague LD; Pletz MW
Int J Antimicrob Agents; 2020 Oct; 56(4):106127. PubMed ID: 32750418
[TBL] [Abstract][Full Text] [Related]
16. [Molecular characterization of beta-lactamase-associated resistance in Acinetobacter baumannii strains isolated from clinical samples].
Keskin H; Tekeli A; Dolapci İ; Öcal D
Mikrobiyol Bul; 2014 Jul; 48(3):365-76. PubMed ID: 25052103
[TBL] [Abstract][Full Text] [Related]
17. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
[TBL] [Abstract][Full Text] [Related]
18. Deciphering Multidrug-Resistant Acinetobacter baumannii from a Pediatric Cancer Hospital in Egypt.
Jalal D; Elzayat MG; Diab AA; El-Shqanqery HE; Samir O; Bakry U; Hassan R; Elanany M; Shalaby L; Sayed AA
mSphere; 2021 Dec; 6(6):e0072521. PubMed ID: 34787450
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020.
Liu PY; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Lee YL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
J Microbiol Immunol Infect; 2022 Oct; 55(5):888-895. PubMed ID: 34521591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
